Advertisement
Advertisement
U.S. Markets open in 22 mins
Advertisement
Advertisement
Advertisement
Advertisement

BrainStorm Cell Therapeutics In (GHDN.SG)

Stuttgart - Stuttgart Delayed Price. Currency in EUR
2.4580+0.5675 (+30.02%)
As of 08:07AM CET. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.8905
Open2.4580
Bid2.6710 x 300000
Ask2.7460 x 300000
Day's Range2.4580 - 2.4580
52 Week Range1.2390 - 4.5710
Volume0
Avg. Volume0
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMar 27, 2023 - Mar 31, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    BrainStorm Cell Therapeutics Partners with NEALS, The ALS Association, and I AM ALS to Provide Public Access to Biospecimens from NurOwn's Phase 3 ALS Study

    BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that BCLI will donate biospecimens from NurOwn's placebo-controlled Phase 3 ALS trial to the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) biorepository for use by the research community. The specimens are being submitted to the biorepository in connection with a $500,000 grant previously awarded to BrainStorm by The ALS Association an

  • PR Newswire

    BrainStorm Cell Therapeutics to Present at Biotech Showcase™ 2023

    BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that Chaim Lebovits, President and CEO, and Stacy Lindborg, Co-CEO, will jointly present a corporate and clinical overview at 10:30 a.m. PT on Monday, Jan. 9 at Biotech Showcase™ 2023 (Hilton San Francisco Union Square, Yosemite A, Ballroom Level). Company management will also be available for one-on-one investor meetings at the conference, which c

  • PR Newswire

    BrainStorm Cell Therapeutics Announces Promotion of Dr. Stacy Lindborg to Co-Chief Executive Officer

    BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the promotion of Dr. Stacy Lindborg to the role of Co-Chief Executive Officer. This promotion launches a targeted capability build which will be led by Dr. Lindborg, to hire and bring expertise inside BrainStorm, preparing for success.

Advertisement
Advertisement